Effects of dolutegravir and lamivudine: A Synthesis of Findings from 15 Studies

  1. Home
  2. Effects of dolutegravir and lamivudine
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of dolutegravir and lamivudine: A Synthesis of Findings from 15 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of dolutegravir and lamivudine: A Synthesis of Findings from 15 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Multiple studies have shown that the combination of dolutegravir and lamivudine is an effective treatment for HIV-1 infection. 5 showed that the combination of dolutegravir and lamivudine is effective in people with suppressed HIV-1, regardless of whether they have the M184V/I mutation. 15 evaluated the safety and efficacy of the combination of dolutegravir and lamivudine in Japanese people living with HIV, and showed positive results. Furthermore, 8 evaluated the safety and efficacy of the combination of dolutegravir and lamivudine in older people with HIV, and showed positive results.

14 showed that switching to dual therapy with dolutegravir and lamivudine is effective in maintaining the treatment effect of people with HIV-1 infection. 12 revealed that switching to the combination of dolutegravir and lamivudine showed good virological suppression and tolerability in people with HIV-1 aged over 65 years. 7 showed that switching to a combination of dolutegravir and lamivudine, or dolutegravir and rilpivirine, showed good virological suppression and tolerability in people with HIV-1 infection.

9 suggested that switching to the combination of dolutegravir and lamivudine could increase blood telomere length in people living with HIV. On the other hand, 6 compared the combination of dolutegravir and lamivudine with the combination of bictegravir, tenofovir alafenamide, and emtricitabine, and found no significant difference in real-life tolerability between the two treatments. 2 is a study that evaluated the effect of UGT1A1 polymorphisms on the pharmacokinetics of dolutegravir. 4 suggests that the combination of dolutegravir and lamivudine is associated with weight gain in people with HIV-1 infection.

10 is a real-world study comparing the combination of dolutegravir and lamivudine with the combination of bictegravir, emtricitabine, and tenofovir alafenamide. This study compared the safety and effectiveness of both treatments. 13 suggests that the combination of dolutegravir and lamivudine shows effectiveness and tolerability in treatment-naive and virologically suppressed treatment-experienced individuals with HIV-1 infection.

Benefits and Risks

Benefits Summary

Multiple studies have shown that the combination of dolutegravir and lamivudine shows good virological suppression and tolerability in people with HIV-1 infection. These studies suggest that the combination of dolutegravir and lamivudine shows effectiveness and tolerability in treatment-naive and virologically suppressed treatment-experienced individuals with HIV-1 infection. Furthermore, these studies revealed that the combination of dolutegravir and lamivudine shows good virological suppression and tolerability in older people with HIV-1 infection. The combination of dolutegravir and lamivudine also suggests potential to increase blood telomere length in people living with HIV. However, this combination has been suggested to be related to weight gain in people with HIV-1 infection.

Risks Summary

The combination of dolutegravir and lamivudine has been suggested to be associated with weight gain in people with HIV-1 infection. This combination has also been suggested to be at risk of neurological side effects. Furthermore, the combination of dolutegravir and lamivudine has also been suggested to be associated with worsening kidney function.

Comparison Between Studies

Commonalities Between Studies

Many studies have shown that the combination of dolutegravir and lamivudine shows good virological suppression and tolerability in people with HIV-1 infection. These studies also suggest that the combination of dolutegravir and lamivudine shows effectiveness and tolerability in treatment-naive and virologically suppressed treatment-experienced individuals with HIV-1 infection. Furthermore, these studies revealed that the combination of dolutegravir and lamivudine shows good virological suppression and tolerability in older people with HIV-1 infection.

Differences Between Studies

There is no consensus between studies on the possibility that the combination of dolutegravir and lamivudine is related to weight gain in people with HIV-1 infection. Weight gain was observed in some studies, while other studies did not observe weight gain.

Consistency and Contradictions of Results

Multiple studies have shown that the combination of dolutegravir and lamivudine is an effective treatment for HIV-1 infection. However, some studies suggest that this combination may be associated with weight gain in people with HIV-1 infection. Further research is needed on this point.

Points to Note Regarding Application to Real Life

The combination of dolutegravir and lamivudine has been shown to be an effective treatment for people with HIV-1 infection. However, this combination has also been suggested to be at risk of weight gain and neurological side effects. Therefore, it is important to pay attention to the patient's weight and neurological symptoms when administering this combination. This combination has also been suggested to be associated with worsening kidney function, so it is important to exercise caution when administering it to patients with worsening kidney function.

Limitations of Current Research

Since all current studies are observational studies, they cannot prove causality. These studies have not fully evaluated the long-term effects of the combination of dolutegravir and lamivudine. Furthermore, these studies have not fully evaluated the effects of genetic polymorphisms on the combination of dolutegravir and lamivudine.

Future Research Directions

Further research is needed to evaluate the long-term effects of the combination of dolutegravir and lamivudine and the effects of genetic polymorphisms on this combination. Future research is needed to develop ways to mitigate the risk of weight gain and neurological side effects from this combination.

Conclusion

The combination of dolutegravir and lamivudine has been shown to be an effective treatment for people with HIV-1 infection. However, this combination has also been suggested to be at risk of weight gain and neurological side effects. Therefore, it is important to pay attention to the patient's weight and neurological symptoms when administering this combination. This combination has also been suggested to be associated with worsening kidney function, so it is important to exercise caution when administering it to patients with worsening kidney function. Further research is needed to evaluate the long-term effects of the combination of dolutegravir and lamivudine and the effects of genetic polymorphisms on this combination.

Literature analysis of 15 papers
Positive Content
15
Neutral Content
0
Negative Content
0
Article Type
2
1
0
0
15
1.

Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.

Author: SongIvy, BorlandJulie, MinSherene, LouYu, ChenShuguang, PatelParul, WajimaToshihiro, PiscitelliStephen C

Drug interactions

This study evaluated the effects of etravirine (ETR) on the pharmacokinetics (PK) of dolutegravir (DTG), an unboosted, once-daily integrase inhibitor. The study found that ETR significantly decreased DTG exposure. The combination of DTG and ETR alone should be avoided; however, DTG may be coadministered with ETR without a dosage adjustment if lopinavir/ritonavir or darunavir/ritonavir is concurrently administered.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics.

Author: ChenShuguang, St JeanPamela, BorlandJulie, SongIvy, YeoAstrid J, PiscitelliStephen, RubioJustin P

Dolutegravir safe for UGT1A1 variants

Carriers of UGT1A1 reduced function polymorphisms did not experience clinically significant increases in dolutegravir exposure, so dose adjustment is not required.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.

Author: JohnsonMark, BorlandJulie, ChenShuguang, SavinaPaul, WynneBrian, PiscitelliStephen

Dolutegravir can be coadministered with boceprevir or telaprevir in patients coinfected with HIV and HCV with no dose adjustment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.

Author: KabraMadhusudan, BarberTristan J, AllavenaClotilde, MarcelinAnne-Geneviève, Di GiambenedettoSimona, PasquauJuan, GianottiNicola, LlibreJosep M, Rial-CresteloDavid, De Miguel-BuckleyRosa, BlickGary, TurnerMatthew, HarrisonCale, WynneTammy, VerdierGustavo, ParryChris M, JonesBryn, OkoliChinyere, DonovanCynthia, PriestJulie, LetangEmilio

Improved virologic response

A meta-analysis investigated the impact of the M184V/I mutation on the virologic response to dolutegravir plus lamivudine in people with HIV. The mutation did not significantly affect the virologic response.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.

Author: RocabertAlba, BorjabadBeatriz, BerrocalLeire, BlanchJordi, InciarteAlexy, ChiviteIvan, Gonzalez-CordonAna, TorresBerta, AmbrosioniJuan, Martinez-RebollarMaria, LagunoMontserrat, De La MoraLorena, FoncillasAlberto, SempereAbiu, RodriguezAna, SolbesEstela, LlobetRoger, MiroJose M, MallolasJosep, BlancoJose L, De LazzariElisa, MartinezEsteban

Bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) and dolutegravir/lamivudine showed no significant difference in the risks of overall or toxicity-related discontinuations or in the profile of adverse events leading to discontinuation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

8.

Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV.

Author: MazzitelliMaria, SassetLolita, GardinSamuele, LeoniDavide, TrunfioMattia, ScaglioneVincenzo, MengatoDaniele, AgostiniElena, VaniaEleonora, PutaggioCristina, CattelanAnnamaria

Efficacy in elderly HIV
Safety in elderly HIV

The combination of dolutegravir and lamivudine (DTG/3TC) is an effective and safe treatment for people living with HIV (PLWH), including those aged 65 and older. Long-term data on this combination therapy in elderly individuals is lacking, but real-life studies show promising results.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study.

Author: LombardiFrancesca, SanfilippoAlessia, FabbianiMassimiliano, BorghettiAlberto, CicculloArturo, TamburriniEnrica, Di GiambenedettoSimona

Improved BTL
Reduced immunosenescence

A study investigated the effects of switching to a dual therapy (DT) with dolutegravir + lamivudine versus maintaining a standard triple therapy (TT) on blood telomere length (BTL) in people living with HIV (PLWH). The study found no significant difference in BTL after one year.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Country of birth is associated with discrepancies in the prescription of two-drug regimens in successfully treated people with HIV in France.

Author: PalichRomain, HentzienMaxime, HocquelouxLaurent, DuvivierClaudine, AllavenaClotilde, HuleuxThomas, MakinsonAlain, ReyDavid, DelobelPierre, CuzinLise,

2DR prescription

People with HIV (PWH) born outside of France were less likely to receive two-drug regimens (2DRs) as a maintenance treatment compared to those born in France, even with unrestricted access to antiretroviral therapy (ART). Older PWH and those with higher CD4+ T-cell counts were more likely to receive 2DRs. Further research is needed to understand the factors influencing physician prescribing practices.

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.

Author: Suárez-GarcíaInés, AlejosBelén, HernandoVictoria, ViñuelaLaura, Vera GarcíaMar, Rial-CresteloDavid, Pérez ElíasMaría Jesús, Albendín IglesiasHelena, PeraireJoaquim, TiraboschiJuan, DíazAsunción, MorenoSantiago, JarrínInma,

High effectiveness
High tolerability

This multicentre cohort study assessed the effectiveness and tolerability of dolutegravir/lamivudine among treatment-naive and virologically suppressed treatment-experienced individuals with HIV. Viral suppression rates were high in both groups, with no significant difference in effectiveness compared to other regimens.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV.

Author: ErgenPınar, BektasBegüm, AydınÖzlem, KeskinHavva, ÜçışıkAyşe Canan, KaradağFatma Yılmaz, CağYasemin

HIV treatment efficacy
Virological blips

A retrospective study of 63 patients living with HIV who switched to dolutegravir (DTG) and lamivudine (3TC) dual therapy found that the regimen was effective and well-tolerated, with no serious adverse effects requiring therapy switch.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Safety and Effectiveness Analyses of Dolutegravir/Lamivudine in Patients with HIV: 2-Year Report of Post-Marketing Surveillance in Japan.

Author: TofukujiAyano, HongoHaruyuki, NagaoTakako, SebataAkemi, SuzukiMiwako, MaenoYuko, KurosakiEiji, FukudaAkiko, WatanabeTomoyuki

HIV treatment

This report evaluates the safety and effectiveness of the two-drug regimen dolutegravir/lamivudine (DTG/3TC) in Japanese people living with HIV (PLHIV) through post-marketing surveillance.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.